Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Use of Midodrine as an Adjunctive Therapy to Liberate Patients from Intravenous Vasopressors: A Systematic Review and Meta-analysis of Randomized Controlled Studies

The Use of Midodrine as an Adjunctive Therapy to Liberate Patients from Intravenous Vasopressors:... BackgroundStudies evaluating the role of midodrine as an adjunctive therapy to liberate patients with shock from intravenous (IV) vasopressors have yielded mixed results. The aim of our study was to evaluate the efficacy and safety of midodrine as an adjunctive therapy to liberate patients with shock from IV vasopressors.MethodsElectronic searches of the MEDLINE, EMBASE, and Cochrane databases through April 2022 for randomized controlled trials (RCTs) that evaluated the use of midodrine versus control in patients with shock and a low dose of IV vasopressors. The primary outcome was total IV vasopressor time, while the secondary outcomes included time-to-IV vasopressor discontinuation, IV vasopressor restart, intensive care unit (ICU) length of stay (LOS), hospital LOS, and incidence of bradycardia.ResultsThe final analysis included four RCTs with a total of 314 patients: 158 in the midodrine group and 156 in the control group, with a weighted mean age of 64 years (54.2% men). There was no significant difference in the total IV vasopressor time between the midodrine and control groups (standardized mean difference [SMD] − 0.53; 95% confidence interval [CI] − 1.38 to 0.32, p = 0.22; I2 = 92%). Also, there were no significant differences between the two groups in the time-to-IV vasopressor discontinuation (SMD − 0.05; 95% CI − 0.57 to 0.47, p = 0.09), IV vasopressor restart (19.3 vs. 28.3%; risk ratio [RR] 0.74; 95% 0.25–2.20, p = 0.59), ICU LOS (SMD − 0.49; 95% CI − 1.30 to 0.33, p = 0.24), and hospital LOS (SMD 0.01; 95% CI − 0.27 to 0.29, p = 0.92). However, compared with the control group, the midodrine group had a higher risk of bradycardia (15.3 vs. 2.1% RR 5.56; 95% CI 1.54–20.05, p = 0.01).ConclusionsAmong patients with vasopressor-dependent shock, midodrine was not associated with early liberation of vasopressor support or shorter ICU or hospital length of stay. Adding midodrine increased the risk of bradycardia. Further large RCTs are needed to better evaluate the efficacy and safety of midodrine in liberating patients from IV vasopressors. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cardiology and Therapy Springer Journals

The Use of Midodrine as an Adjunctive Therapy to Liberate Patients from Intravenous Vasopressors: A Systematic Review and Meta-analysis of Randomized Controlled Studies

Download PDF
11 pages

Loading next page...
 
/lp/springer-journals/the-use-of-midodrine-as-an-adjunctive-therapy-to-liberate-patients-bMEMU0i1qm
Publisher
Springer Journals
Copyright
Copyright © The Author(s) 2023
ISSN
2193-8261
eISSN
2193-6544
DOI
10.1007/s40119-023-00301-0
Publisher site
See Article on Publisher Site

Abstract

BackgroundStudies evaluating the role of midodrine as an adjunctive therapy to liberate patients with shock from intravenous (IV) vasopressors have yielded mixed results. The aim of our study was to evaluate the efficacy and safety of midodrine as an adjunctive therapy to liberate patients with shock from IV vasopressors.MethodsElectronic searches of the MEDLINE, EMBASE, and Cochrane databases through April 2022 for randomized controlled trials (RCTs) that evaluated the use of midodrine versus control in patients with shock and a low dose of IV vasopressors. The primary outcome was total IV vasopressor time, while the secondary outcomes included time-to-IV vasopressor discontinuation, IV vasopressor restart, intensive care unit (ICU) length of stay (LOS), hospital LOS, and incidence of bradycardia.ResultsThe final analysis included four RCTs with a total of 314 patients: 158 in the midodrine group and 156 in the control group, with a weighted mean age of 64 years (54.2% men). There was no significant difference in the total IV vasopressor time between the midodrine and control groups (standardized mean difference [SMD] − 0.53; 95% confidence interval [CI] − 1.38 to 0.32, p = 0.22; I2 = 92%). Also, there were no significant differences between the two groups in the time-to-IV vasopressor discontinuation (SMD − 0.05; 95% CI − 0.57 to 0.47, p = 0.09), IV vasopressor restart (19.3 vs. 28.3%; risk ratio [RR] 0.74; 95% 0.25–2.20, p = 0.59), ICU LOS (SMD − 0.49; 95% CI − 1.30 to 0.33, p = 0.24), and hospital LOS (SMD 0.01; 95% CI − 0.27 to 0.29, p = 0.92). However, compared with the control group, the midodrine group had a higher risk of bradycardia (15.3 vs. 2.1% RR 5.56; 95% CI 1.54–20.05, p = 0.01).ConclusionsAmong patients with vasopressor-dependent shock, midodrine was not associated with early liberation of vasopressor support or shorter ICU or hospital length of stay. Adding midodrine increased the risk of bradycardia. Further large RCTs are needed to better evaluate the efficacy and safety of midodrine in liberating patients from IV vasopressors.

Journal

Cardiology and Therapy – Springer Journals

Published: Mar 1, 2023

Keywords: Midodrine; Vasopressors; Shock; Intensive care unit; ICU; Critical care

References

  • Clinical utility of midodrine and methylene blue as catecholamine-sparing agents in intensive care unit patients with shock
    Tchen, S; Sullivan, JB
  • Current use of vasopressors in septic shock
    Scheeren, TWL; Bakker, J; De Backer, D
  • Circulatory shock
    Vincent, JL; De Backer, D
  • Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (the MIDAS trial)
    Anstey, MH; Wibrow, B; Thevathasan, T
  • Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions
    Levine, AR; Meyer, MJ; Bittner, EA
  • Vasoplegia treatments: the past, the present, and the future
    Levy, B; Fritz, C; Tahon, E
  • Mechanisms of vascular hyporesponsiveness in septic shock
    Kimmoun, A; Ducrocq, N; Levy, B
  • Midodrine improves clinical and economic outcomes in patients with septic shock: a randomized controlled clinical trial
    Adly, DHE; Bazan, NS; El Borolossy, RM
  • Assessment of costs of avoidable delays in intensive care unit discharge
    Bagshaw, SM; Tran, DT; Opgenorth, D
  • Characteristics, outcomes and costs of prolonged stay ICU patients
    Aygencel, G; Turkoglu, M
  • Efficacy of midodrine vs placebo in neurogenic orthostatic hypotension. A randomized, double-blind multicenter study. Midodrine Study Group
    Low, PA; Gilden, JL; Freeman, R
  • Effect of oral vasopressors used for liberation from intravenous vasopressors in intensive care unit patients recovering from spinal shock: a randomized controlled trial
    Ahmed Ali, AT; Abd El-Aziz, MA; Mohamed Abdelhafez, A
  • Effect of midodrine versus placebo on time to vasopressor discontinuation in patients with persistent hypotension in the intensive care unit (MIDAS): an international randomised clinical trial
    Santer, P; Anstey, MH; Patrocinio, MD
  • A pilot, feasibility, randomised controlled trial of midodrine as adjunctive vasopressor for low-dose vasopressor-dependent hypotension in intensive care patients: the MAVERIC study
    Costa-Pinto, R; Yong, ZT; Yanase, F
  • The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration
    Liberati, A; Altman, DG; Tetzlaff, J
  • The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials
    Higgins, JPT; Altman, DG; Gøtzsche, PC
  • Measuring inconsistency in meta-analyses
    Higgins, JPT; Thompson, SG; Deeks, JJ
  • 15010: impact of adjuvant use of midodrine in septic patients receiving vasopressors in the ICU setting
    Hailu, K; Allen, B; Rottman-Pietrzak, K
  • 924: adjunctive oral midodrine use in critically ill patients
    Fiorenza, M; Barkes, J; Naik, S
  • 200: impact of oral midodrine on duration of intravenous vasopressor therapy
    Roach, E; Adie, S; Gowan, M
  • The impact of midodrine on duration of vasopressor infusion in patents with septic shock in a community hospital setting
    Nadhim, A; Tun, Z; Chua, LC
  • Oral midodrine is effective for the treatment of hypotension associated with carotid artery stenting
    Sharma, S; Lardizabal, JA; Bhambi, B
  • Feasibility, utility, and safety of midodrine during recovery phase from septic shock
    Whitson, MR; Mo, E; Nabi, T
  • Midodrine for the weaning of vasopressor infusions
    Poveromo, LB; Michalets, EL; Sutherland, SE
  • Impact of adjuvant use of midodrine to intravenous vasopressors: a systematic review and meta-analysis
    Al-Abdouh, A; Haddadin, S; Matta, A
  • Alpha 1-adrenoceptors: function and phosphorylation
    Garcia-Sainz, JA; Vazquez-Prado, J; del Carmen, ML
  • A double-blind, dose-response study of midodrine in neurogenic orthostatic hypotension
    Wright, RA; Kaufmann, HC; Perera, R
  • Pharmacodynamics of midodrine, an antihypotensive agent
    Zachariah, PK; Bloedow, DC; Moyer, TP
  • The bioavailability of midodrin and alpha-2,5-dimethoxyphenyl-beta-aminoethanol hydrochloride
    Grobecker, H; Kees, F; Linden, M